A combination of four phages engineered with a CRISPR–Cas payload can reduce the burden of Escherichia coli infections in animal models without inducing the host immune response.
References
Selle, K. et al. mBio 11, e00019-20 (2020).
Gencay, Y. E. et al. Nat. Biotechnol. https://doi.org/10.1038/s41587-023-01759-y (2023).
Eskenazi, A. et al. Nat. Commun. 13, 302 (2022).
Bikard, D. et al. Nat. Biotechnol. 32, 1146–1150 (2014).
Citorik, R. J., Mimee, M. & Lu, T. K. Nat. Biotechnol. 32, 1141–1145 (2014).
Mu, A. et al. Microbiome 9, 92 (2021).
Nale, J. Y. & Clokie, M. R. Curr. Opin. Biotechnol. 68, 310–317 (2021).
Górski, A., Borysowski, J. & Międzybrodzki, R. Antibiotics 9, 827 (2020).
Dedrick, R. M. et al. Nat. Med. 25, 730–733 (2019).
Hou, K. et al. Sig. Transduct. Target. Ther. 7, 135 (2022).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Lewis, J.M., Sagona, A.P. Armed phages are heading for clinical trials. Nat Microbiol 8, 1191–1192 (2023). https://doi.org/10.1038/s41564-023-01415-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41564-023-01415-w
- Springer Nature Limited